帕金森病：卡比多巴、恶心与运动障碍[撤回]
Parkinson's Disease: Carbidopa, Nausea, and Dyskinesia [Retraction].
出版信息
Clin Pharmacol. 2021 Mar 3;13:43. doi: 10.2147/CPAA.S308259. eCollection 2021.
Abstract
[This retracts the article DOI: 10.2147/CPAA.S72234.].
摘要
[本文撤回文章DOI：10.2147/CPAA.S72234。]
相似文献
1
Parkinson's Disease: Carbidopa, Nausea, and Dyskinesia [Retraction].帕金森病：卡比多巴、恶心与运动障碍[撤回]
Clin Pharmacol. 2021 Mar 3;13:43. doi: 10.2147/CPAA.S308259. eCollection 2021.
2
The Parkinson's Disease Death Rate: Carbidopa and Vitamin B6 [Retraction].帕金森病死亡率：卡比多巴与维生素B6[撤回声明]
Clin Pharmacol. 2021 Mar 3;13:41. doi: 10.2147/CPAA.S308256. eCollection 2021.
3
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.左旋多巴-卡比多巴肠凝胶对晚期帕金森病患者运动障碍的影响。
Mov Disord. 2016 Apr;31(4):530-7. doi: 10.1002/mds.26528. Epub 2016 Jan 28.
4
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.对处于剂末现象的帕金森病患者使用息宁（卡比多巴、左旋多巴和恩他卡朋）的耐受性和安全性进行的开放标签评估。
J Neural Transm (Vienna). 2005 Feb;112(2):221-30. doi: 10.1007/s00702-004-0184-1. Epub 2004 Oct 22.
5
Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.左旋多巴-卡比多巴肠凝胶持续输注治疗帕金森病
J Comp Eff Res. 2014 Jul;3(4):331-3. doi: 10.2217/cer.14.33.
6
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.来自GLORIA注册研究中基线存在运动障碍的患者亚组中的左旋多巴-卡比多巴肠凝胶。
Neurodegener Dis Manag. 2019 Feb;9(1):39-46. doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14.
7
Parkinson's Disease: Carbidopa, Nausea, and Dyskinesia [Expression of Concern].帕金森病：卡比多巴、恶心与运动障碍[关注声明]
Clin Pharmacol. 2020 Apr 23;12:45. doi: 10.2147/CPAA.S240233. eCollection 2020.
8
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.帕金森病的严重程度是峰值剂量运动障碍的一个风险因素。
J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):224-6. doi: 10.1136/jnnp.53.3.224.
9
Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.卡比多巴/左旋多巴缓释胶囊（息宁控释片（Rytary(®)），Nuient™）：帕金森病治疗综述
CNS Drugs. 2016 Jan;30(1):79-90. doi: 10.1007/s40263-015-0306-3.
10
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.美国在门诊开始使用左旋多巴-卡比多巴肠凝胶治疗晚期帕金森病的现行做法。
Adv Ther. 2019 Sep;36(9):2233-2246. doi: 10.1007/s12325-019-01014-4. Epub 2019 Jul 5.
引用本文的文献
1
Enhanced catalytic stability for L-Dopa synthesis through cross-linking of Al₂O₃ nanocrystals with Bacillus subtilis tyrosine hydroxylase.通过将氧化铝纳米晶体与枯草芽孢杆菌酪氨酸羟化酶交联来增强L-多巴合成的催化稳定性。
World J Microbiol Biotechnol. 2025 Jul 28;41(8):282. doi: 10.1007/s11274-025-04492-7.
Zotero 插件